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Structured Summary 
Aim 
Systematically review the frequency and type of adverse events associated with a single dose 
of intravenous or intramuscular gentamicin in adults, for any indication, in studies where a 
comparator was available. 
 
Methods 
A review protocol was developed and registered (PROSPERO: CRD42013003229). Studies 
were eligible for review if they; recruited participants ≥16 years old, used gentamicin 
intramuscularly or intravenously as a single one-off dose, compared gentamicin to another 
medication or placebo, and if adverse events were monitored. We searched MEDLINE, 
EMBASE, Cochrane Library, trial registries, conference proceedings and other relevant 
databases. Risk of bias was assessed on all included studies, including an evaluation of how 
toxicity was defined, the monitoring schedule, analysis of adverse events and blinding. 
 
Results 
15,522 records were identified. After removal of duplicates, screening of title/abstracts for 
relevance and independent selection of full texts by two reviewers, 38 studies were included. 
48,188 participants were analysed of whom 24,014 received a single one-off dose of 
gentamicin (doses ranged from 1mg/kg - 480mg). Acute kidney injury was described in 2532 
participants in the gentamicin group and 1438 in the comparator arm but was reversible in the 
large majority of cases. There were three cases of ototoxicity reported in patients receiving 
gentamicin, with a similar frequency reported in the comparator group. A meta-analysis was 
not performed due to study heterogeneity. The quality of reporting adverse events was poor 
in the majority of studies and the risk of bias was generally high. 
 
Conclusions 
A significant number of patients saw a transient rise in creatinine after a single dose of 
gentamicin at doses up to 480mg. Persistent renal impairment and other adverse events were 
relatively rare. 
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Introduction 
Gentamicin is a well-established antibiotic initially discovered in 1963(1) which is 
particularly useful for treating bacteria resistant to other antimicrobials. It has bactericidal 
and bacteriostatic activity and is effective against both gram-negative and gram-positive 
organisms. Gentamicin is not metabolised but distributed essentially unchanged within the 
extracellular space before excretion in the kidneys by glomerular filtration.(2) Its use is 
limited by potentially serious adverse effects, most commonly ototoxicity and nephrotoxicity.  
 
Ototoxicity, which can be irreversible, encompasses both vestibulotoxicity and 
cochleotoxicity.(3) Gentamicin is primarily vestibulotoxic(4), causing damage to the 
vestibular apparatus, initially affecting the cristae and progressing to the striolar regions of 
the maculi(5). Clinically this leads to dizziness, ataxia and nystagmus. Destruction of the 
auditory sensory cells of the organ of Corti leads to cochleotoxicity which is associated with 
over-production of oxidative free radicals(6) and can present as hearing loss or tinnitus. The 
ototoxicity of aminoglycosides does not correlate with drug levels in the fluid of the inner 
ear, drug dose or gentamicin serum concentration.(7, 8) In a study of 30 patients with 
gentamicin associated vestibulotoxicity, 16 had received less than the recommended 
maximum dose of 5mg/kg/day over 10 days.(8) A review of aminoglycoside toxicity 
including papers published between 1975 and 1982 identified 8 studies (559 patients) that 
evaluated gentamicin(9) and found the frequency of vestibulotoxicity to be 2.7%, and of 
cochlear toxicity 8.3%.(9). A subsequent review in 2008, using different inclusion criteria, 
assessed 4 additional studies (147 patients) and found a frequency of vestibulotoxicity of 
10.9% one week after completing treatment.(10) This review did not comment on cochlear 
toxicity and neither review assessed the effect of duration of therapy on risk of ototoxicity. In 
a case series of 33 patients with permanent gentamicin-induced vestibulotoxicity, 1 patient 
had developed vestibular toxicity after 5 days of treatment; all other patients had received a 
longer course of gentamicin.(11) In a larger case series, 6 of 103 patients presenting to a 
balance disorder clinic with a diagnosis of severe, symmetrical, selective, bilateral vestibular 
loss, had received only a single dose of gentamicin.(10) The lack of correlation between drug 
dose or serum concentration in causing vestibular or cochlear toxicity makes it difficult to 
predict which patients will be affected. Increasing age(12) and a mitochondrial DNA 
mutation, (m.1555A>G),(13, 14) have both been shown to increase a patient’s susceptibility 
to cochleotoxicity, but not vestibulotoxicity. 
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In contrast, nephrotoxicity does appear to be dose related.(15) Re-uptake of the drug occurs 
in the proximal renal tubule where it leads to high drug concentrations within the tubule 
cells.(16) The risk of nephrotoxicity can be minimised by serum-level monitoring with dose 
adjustment, and shortening the duration of treatment.(17) Nephrotoxicity causes tubular 
necrosis (18) and manifests clinically as either non-oliguric renal failure or abrupt onset 
oliguric renal failure. Unlike ototoxicity, renal damage is usually reversible, although full 
recovery can take weeks or months.(19) Several risk factors are thought to predispose to 
nephrotoxicity including increasing age, pre-existing renal disease, use of diuretics, exposure 
to radiographic contrast, circulating volume depletion and use of other nephrotoxic 
medication including ACE inhibitors, NSAIDs, amphotericin or cisplatin.(20-23) The 
frequency of gentamicin related nephrotoxicity is reported to be 10-25%.(24-26) 
 
Other adverse effects reported with gentamicin include hypersensitivity, anaemia, blood 
dycrasias, purpura, stomatitis, convulsions, abnormal liver function, nausea, vomiting and 
rash. More rarely patients on prolonged therapy have developed hypomagnesaemia or colitis, 
and occasionally neurotoxicity leading to encephalopathy, confusion, lethargy, depression 
and hallucinations.(27) 
 
Gentamicin was previously given as a multi dose regimen each day, modified according to 
serum drug levels. Several studies have shown that single-daily dosing of gentamicin offers 
an equal, if not improved, toxicity profile.(28) However, the toxicity profile of a single one 
off dose of gentamicin, as opposed to multiple doses over several days, remains unclear. A 
single dose is used as a prophylaxis prior to surgery or invasive procedures, such as 
endoscopic retrograde cholangio-pancreatography, and has also been proven to be effective in 
the treatment of gonorrhoea.(29-31) It is possible that a one off dose is less toxic and may 
have a lower risk of adverse effects. Previous systematic reviews of gentamicin safety have 
focused on a specific indication for use(32), drug preparation(33), treatment population(34), 
individual adverse effect(35) or dosing regimen(23), but none have evaluated single dose 
gentamicin. The aim of this systematic review was to assess the frequency and type of 
adverse events associated with the use of a single dose of intravenous or intramuscular 
gentamicin in adults. 
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Methods 
 
A systematic review protocol was developed and registered with PROSPERO at the Centre 
for Reviews and Dissemination, University of York (Reg No. CRD42013003229 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42013003229).  
 
Eligibility Criteria 
Studies were considered eligible for the review if they fulfilled the following criteria; human 
participants; male or female; ≥16 years old; intramuscular or intravenous gentamicin as a 
single one-off dose; control group; adverse effects monitored. The control group could 
comprise of any of the following; placebo, no treatment, an antimicrobial regimen which did 
not include gentamicin, or a regimen that included gentamicin in conjunction with other 
antimicrobials. No other restriction on study design was applied. There was no restriction on 
the indication for treatment, dose of gentamicin, length of follow up, clinical setting in which 
gentamicin was given, year of publication or publication status. 
 
Search strategy 
The following electronic databases were searched; The Cochrane Library (including the 
Health Technology Assessment database), MEDLINE, EMBASE, British Nursing Index and 
Cumulative Index Nursing and Allied Health Literature (CINAHL). The following were 
searched specifically for systematic reviews and guidelines: National Guideline 
Clearinghouse, NICE and SIGN. Ongoing trials were sought through the following trial 
registers; clinicaltrials.gov, WHO International Clinical Trials Registry Platform (ICTRP) 
and Current Controlled Trials. Conference abstracts and proceedings were searched using 
zetoc and Conference Proceedings Citation Index (CPCI), for all years available. 
Dissertations and theses were searched using ProQuest, Index to Theses in Great Britain and 
Ireland and EThOS. Specific sources of drug information were searched, including 
pharmacovigilance data from regulatory authorities (electronic Medicines Compendium 
[eMC], US Food and Drug Administration [FDA] and Medicines and Healthcare products 
Regulatory Agency [MHRA]) and a specific drug bibliographic database (TOXLINE). 
Citation searching was carried out on included articles. In order to identify grey literature, the 
National Technical Information Service (NTIS) and OpenGrey were searched. Scoping 
searches were carried out to refine the search strategy. The initial search was carried out in 
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the first week of February 2013, with an update search carried out in the first week of 
November 2016. An example of the search strategy used for one large database is available in 
Online Appendix 1. Where the full search strategy could not be used the word ‘gentamicin’ 
and its alternatives were searched for separately. 
 
Study selection 
All identified records were entered into Reference Manager Version 11.0 and duplicates 
removed. Titles and, where available, abstracts were screened by one reviewer for relevance, 
using the eligibility criteria. Due to the number of records it was not feasible for two 
independent reviewers to carry out this process but as a check for consistency 10% of records 
were randomly selected, using a random number generator, and screened independently by a 
second reviewer. Full text articles were sought for all potentially relevant records. Inclusion 
and exclusion criteria were applied independently to all full articles, by one reviewer. Due to 
the number of articles the application of the inclusion and exclusion criteria by a second 
reviewer was split between four different individuals. Any disagreement between the two 
reviewers was resolved by discussion or by a third independent reviewer when necessary. 
Foreign language records were included when searching, and titles and abstracts were 
translated to allow screening. All potentially relevant foreign language studies were translated 
for assessment and, if appropriate, data extraction. 
  
Data extraction 
The data extraction form (Online Appendix 2) was designed and piloted on five studies. Data 
extraction was carried out independently by two reviewers on all included studies. The 
following study characteristics were collected: 1) author; 2) study design; 3) country of 
publication; 4) number of participants; 5) age range of participants; 6) gender of participants; 
7) dose of gentamicin; and 8) indication for gentamicin. Specific details about adverse events 
were collected for the gentamicin and comparator group including: 1) number of participants 
2) frequency of adverse events; 3) type of adverse events; and 4) length of follow up. 
 
Risk of bias assessment 
Risk of bias assessment was included within the data extraction form and was independently 
assessed by two reviewers. Risk of bias was assessed with a tool specific to the study 
design.(36-38)  
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Data synthesis 
Characteristics, main findings and risk of bias assessment were tabulated for each study. If 
data were appropriate for meta-analysis, we planned that results be presented as a summary 
risk ratio with 95% confidence intervals, on an intention-to-treat basis. 
 
Results 
The literature search identified 15,522 records, of which 6858 were exact duplicates, leaving 
8,664 unique studies. Many of the duplicates were generated when searching TOXLINE 
database which generates a separate output for each search term (e.g. gentamicin, gentamycin 
and cidomycin). Due to the number of records, only one reviewer screened all the articles for 
relevance. A second reviewer screened 10% (n=880) of the records to assess consistency and 
agreement between reviewers was moderate, Kappa coefficient 0.561 (95% CI: 0.499 to 
0.624). When assessing the eligibility of full-text articles we found that some studies 
recruited both children and adults but none provided separate analysis by age group. Studies 
where the large majority (≥ 80%) of participants were <16 years old were excluded. The flow 
diagram for study selection is shown in Figure 1.  
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Figure 1: PRISMA Flow Diagram for the Systematic Review of the Adverse Effects of Single Dose Gentamicin in Adults 
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Characteristics of included studies 
38 studies were included in the final synthesis; one thesis (39),  and 37 journal articles (30, 
40-75). Two (76, 77) additional trial protocols were identified via ClinicalTrials.gov had not 
reported results at the time of writing, so were excluded.  The 38 studies included 13 
randomised controlled studies (two crossover designs), 18 cohort studies, one retrospective 
survey, three pharmacokinetic and three quasi experimental studies. In keeping with our 
background understanding and scoping searches, no existing systematic review evaluating the 
safety of single dose gentamicin was identified. 
 
Across all the included studies, 24,163 participants received a single one-off dose of 
gentamicin. Ages ranged from 18-95 years old and the dose of gentamicin ranged from 
1mg/kg to 480mg. Indications for a single dose of gentamicin included prophylaxis prior to 
or during surgery, cystogram or transrectal prostate biopsy. It was also used to treat sepsis, 
gonorrhoea, urinary tract infections and acute pyelonephritis. Table 1 shows the 
characteristics of all included studies. 
 
 * Ideal Body Charts based on height and gender, no further details. † Possible overlap in data.  ǂ Gender data is greater than total number of participant 
 
Table 1: Characteristics of Included Studies 
 
Study 
(Year of publication) 
Design Country Total number 
participants 
enrolled (those 
receiving 
gentamicin) 
Age Range 
(years) 
Gender Dose and route of 
Gentamicin 
Indication for Gentamicin Length of 
follow up 
Adelman et al(53) 
(1982) 
RCT Crossover USA 10  (10) Not available Not available 1mg/kg/hr                        IV Nil, pharmacokinetic study 30 days 
Ahmed et al(70) 
(2016) 
Cohort UK 1500  (756) Not available Male = 384 
Female = 1116 
5mg/kg (max 480mg)      IV 
2mg/kg renal impairmentIV 
Preoperative prophylaxis, hip-
fracture patients 
30 days 
Bailey et al(49) 
(1996) 
RCT New Zealand 53  (26) 18-68 Male = 5 
Female = 48 
10mg/kg/hr                      IV Treatment of acute pyelonephritis 7-10 days 
Bailey et al(65) 
 
(2014) 
Cohort UK 560  (254) Not available Male = 245 
Female = 247 
Excluded = 68 
‘Ideal Body Weight’ 
charts*                             IV 
Surgical prophylaxis, elective 
total hip or knee replacement 
23 months 
Bell et al†(64) 
(2014) 
Cohort UK 12883  (6655) Not available Data or 
publication error ǂ 
4mg/kg                             IV Surgical prophylaxis 1 year 
Challagundla et al(60) 
(2013) 
Cohort UK 198  (98) 39-95 Male = 81 
Female = 117 
160mg (>60kg)                IV 
120mg (<60kg)                IV 
Surgical prophylaxis, elective 
total hip or knee replacement 
6 months 
Cobussen et al(71) 
(2016) 
Cohort Netherlands 302 (179) Not available Male = 155 
Female = 147 
4.7mg/kg +/- 0.7 (SD)     IV Treatment of sepsis in emergency 
department 
28 days 
Contrepois et al(52) 
(1985) 
RCT Crossover France 33  (6) 21-28 Male = 33 1mg/kg/hr                        IV Nil, pharmacokinetic study Not available 
Craig et al(74) 
(2012) 
Matched Cohort UK 200 (100) Not available Male = 56 
Female = 144 
240mg                              IV Preoperative prophylaxis,  hip-
fracture patients 
7 days 
Craxford et al(67) 
(2014) 
Cohort UK 400 (200) 40-91 Not available 3mg/kg                             IV Surgical prophylaxis, elective 
total hip or knee replacement 
1 year 
Craxford et al(66) 
(2014) 
Cohort UK 180  (90) Not available Not available 2mg/kg                             IV Prophylaxis, spinal surgery Not available 
Creasey et al(57) 
(1984) 
Pharmacokinetic USA 48  (12) 19-32 Male = 48 80mg                                IV Nil, pharmacokinetic study 24hr 
Dobbs et al(47) 
(1976) 
Quasi experimental 
Crossover 
UK 6  (6) 20-49 Not available 80mg                                IV Nil, experimental 1 month 
Dubrovskaya et al(69) 
(2015) 
Cohort USA 4177  (1590) Not available Male = 1659 
Female = 2518 
Weight based 
160mg–400mg                 IV 
Perioperative prophylaxis, 
orthopaedic surgery 
5 days 
Fried et al(45) 
 
(1996) 
RCT USA 142  (72) 19-90 Male = 107 
Female = 35 
1.5mg/kg                         IM Prophylaxis prior to 
cystometrogram and/or cystogram 
studies 
1-2 weeks 
Giri et al(58) 
(2016) 
RCT India 100 (50) 18-80 Male = 49 
Female = 51 
5mg/kg                             IV Surgical prophylaxis 1 month 
Hira et al(44) 
(1985) 
RCT Zambia 415  (302) Not available Male = 415 280mg                             IM Uncomplicated gonococcal 
urethritis 
14 days 
Jahre et al(56) 
(1978) 
Pharmacokinetic USA 6  (6) Not available Not available 1mg/kg                            IM Nil, pharmacokinetic study 24hr – 1 month 
 * Ideal Body Charts based on height and gender, no further details. † Possible overlap in data.  ǂ Gender data is greater than total number of participant 
 
Jettoo et al(59) 
(2013) 
Matched Cohort UK 220  (107) Not available Male = 52 
Female = 168 
5mg/kg                             IV Prophylaxis, hip hemiarthroplasty 
for femoral neck fractures 
180 days 
Kirkcaldy et al(30) 
 
(2014) 
RCT USA 614  (305) Not available Male = 491 
Female = 121 
Data missing = 2 
240mg(>45kg) or 
5mg/kg(<45kg)               IM 
Treatment of gonorrhoea 30 days 
Kleinschmidt et al(46) 
(1983) 
RCT Germany 65  (34) 18-61 Female = 65 120mg                             IM Treatment of cystitis 4-6 weeks 
Lorber et al(73) 
 
(2013) 
Retrospective survey Israel 1666  (1085) Not available Male = 1666 80mg                               IM 
160mg                             IM 
240mg                             IM 
Prophylaxis, transrectal prostate 
biopsy 
10 days 
McEntee et al(48) 
(1987) 
RCT UK 61  (17) Not available Male = 61 80mg                                IV Prophylaxis in high risk patients 
undergoing prostatectomy 
Not available 
Meyers et al(55) 
 
(1972) 
Pharmacokinetic USA 20  (7, 3, 6) 22-30 Male = 11 
Female = 9 
100mg                             IM 
1mg/kg                             IV 
1.5mg/kg                          IV 
Nil, pharmacokinetic study 8 hours 
Mukherjee et al(62) 
(2013) 
Cohort UK 63 (40) Not available Male = 48 
Female = 15 
Not available                   IV Perioperative prophylaxis, radical 
cystectomy 
2 days, unclear 
if longer 
Ndele(39) Quasi experimental 
Crossover 
Not available 6  (6) 28-45 Male = 6 120mg                              IV Nil, experimental 1 month 
Nielson et al(61) 
(2013) 
Cohort Denmark 3461  (1716) Not available Not available 
Excluded = 438 
240mg (<120kg)              IV 
480mg (≥120kg)              IV 
Prophylaxis, cardiac surgery 3 days 
Nielson et al(68) 
(2014) 
Cohort Denmark 1336  (668) 50-78 Male = 966 
Female = 370 
240mg (≤120kg)              IV 
480mg (>120kg)              IV 
Preoperative prophylaxis, cardiac 
surgery 
1 year 
Pareek et al(50) 
(1981) 
Quasi experimental Saudia Arabia 40  (20) Not available Not available 160mg                             IM Treatment of gonorrhoea Not available 
Pons et al(43) 
(1993) 
RCT USA 910  (404) Not available Not available 80mg                                IV Preoperative prophylaxis 3 months 
Rakovec et al(54) 
(1985) 
Cohort Yugoslavia 1004  (572) Not available Male = 513 
Female = 491 
80mg                                IV Preoperative prophylaxis, 
colorectal surgery 
Not available 
Ross et al(75) 
 
(2013) 
Cohort UK 281 (149) 53-91 Male = 118 
Female = 155 
Excluded = 8 
4mg/kg                             IV Preoperative prophylaxis, hip and 
knee arthroplasty 
3 or 4 days 
Rowlands et al(40) 
(1982) 
RCT UK 129  (67) 18-60+ Not available 120mg                              IV Intraoperative prophylaxis, 
emergency abdominal surgery 
4 weeks 
Solgaard et al(41) 
(2000) 
Cohort Denmark 163  (93) 31-101 Male = 37 
Female = 126 
240mg                              IV Preoperative prophylaxis 7 days 
Sprowson et al(63) 
(2013) 
Cohort UK 8195  (2101) Not available Not available 4.5mg/kg                          IV Preoperative prophylaxis, primary 
joint arthroplasty 
30 days 
Sundman et al(42) 
 
(1997) 
RCT Sweden 158  (54) 20-94 Male = 57 
Female = 44 
Excluded = 57 
3mg/kg                             IV Febrile UTI requiring 
hospitalisation 
12-21 days 
Walker et al†(72) 
(2016) 
Cohort UK 9242  (6267) Not available Male = 3849 
Female = 5393 
4mg/kg                             IV Prophylaxis, orthopaedic surgery, 
excluding NOF repair 
1 year 
Wenzel et al(51) 
(1985) 
RCT Germany 60  (30) 45-84 Male = 21 
Female = 39 
80mg                                IV Preoperative prophylaxis, elective 
colonic surgery 
Not available 
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Risk of bias assessment 
The risk of bias for each study is summarised in Figure 2. Monitoring and reporting of 
adverse events varied greatly between studies. The definition of adverse events was poorly 
reported, especially for older studies. Information about allocation concealment and blinding 
at the time of adverse event reporting was not recorded for the majority of studies. Reporting 
of adverse events frequently lacked detail, making it difficult to assess the risk of bias 
accurately. However, most studies did provide numerical data on adverse event rates 
according to intervention group 
 
Figure 2: Risk of bias assessment of included studies 
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Reported adverse events are summarised in Table 2. Twenty four (30, 41, 43, 45, 49, 54, 57-
72, 74, 75), of the 38 included studies, reported adverse events in the gentamicin arm of their 
study although not all adverse events were related to gentamicin. Pons et al (43), the largest 
randomised controlled trial, had 910 participants who received ceftizoxime, or gentamicin 
plus vancomycin as antimicrobial prophylaxis prior to neurosurgery. Adverse events were not 
the primary outcome, but serum creatinine and urea were measured pre and 48hrs post 
operatively. There were no adverse drug reactions in the ceftizoxime group and six reactions 
reported in the gentamicin plus vancomycin group. All six reactions were ‘significant 
hypotension and/or flushing’, consistent with red man syndrome, a known adverse reaction 
associated with vancomycin. The first 186 patients enrolled into this study had a 
‘comprehensive review, urinalysis and serum studies’ and ‘there was no evidence of 
haematological, metabolic, hepatic or renal toxicity in either group’. Mean pre-treatment 
serum creatinine was 79.56 µmol/L in the ceftizoxime group and 76.02 µmol/L in the 
gentamicin plus vancomycin group. Post-treatment mean creatinine was 73.37 µmol/L and 
70.72 µmol/L respectively. Although the paper concludes that ceftizoxime is less toxic than 
vancomycin plus gentamicin, this seems to be based on the adverse event data associated 
with vancomycin. 
 
Fried et al (45) compared a single dose of gentamicin with an alternative antibiotic regimen 
(chosen on the basis of urine culture and sensitivity testing three weeks earlier) given as 
prophylaxis prior to cystometrogram and/or cystogram. The study’s main focus was clinical 
outcome and cost effectiveness. It was quasi-randomised with patients divided into groups 
based on whether their medical record number ended in an odd or even number. Seventy 
patients were included in the oral antibiotic group and 72 in the gentamicin group, mostly 
treated as outpatients. No differences in adverse events were found between the two groups. 
This study also asked participants in both groups to rate the ‘comfort’ and ‘convenience’ of 
treatment, on a scale of 1-5 (1=poor and 5=excellent). The gentamicin injection was 
preferable to oral antibiotics, with a mean convenience score of 4.42 in the gentamicin group 
compared to 3.63 in the oral antibiotic group and a mean comfort score of 4.24 in the 
gentamicin group compared to 3.83 in the oral antibiotic group. 
 
Kirkcaldy et al (30) was the most recent, large randomised controlled trial assessing single 
dose gentamicin. Comprehensive monitoring for adverse events was undertaken with a high 
and equal frequency of adverse events in both arms of the trial. Nausea, vomiting and 
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diarrhoea were the most commonly reported events and were attributed to azithromycin, 
which was given in both arms of the trial. No serious adverse events were reported over 30 
days of follow-up. No specific monitoring for nephrotoxicity or ototoxicity was undertaken. 
 
Creasey et al (57) assessed the pharmacokinetic interaction between aztreonam and a number 
of other antibiotics, including gentamicin. There was one reported side effect in the 
gentamicin group comprising a transient rise in glutamic pyruvic transaminase, a liver 
enzyme. 
 
A significant number of studies (58-75) have been published in the last three years, almost as 
many as in the previous 50 years. The majority of these recent studies are a form of cohort 
study, without randomisation. Many of the studies reviewed a change in local antibiotic 
policies, particularly within orthopaedic surgery (59, 60, 63, 65, 67, 69, 70, 72, 74, 75). 
Authors compared a cephalosporin with gentamicin plus another antibiotic, frequently 
flucloxacillin. The studies focused on renal impairment with little or no mention of other 
adverse events. It should be noted that there is a possible overlap of data between studies by 
Bell et al (64) and Walker et al (72). Walker et al (72) presented data from NHS Tayside, 
orthopaedic department between October 2008 and December 2013 which may also be 
included with the study by Bell et al (64) covering five surgical specialities (including 
orthopaedic surgery) in NHS Tayside between October 2006 and September 2010.  
 
Challagundlla et al (60) divided patients into four groups, high dose flucloxacillin plus 
gentamicin, low dose flucloxacillin plus gentamicin, and two groups receiving cefuroxime 
(data collected retrospectively and prospectively). The dose of gentamicin was the same in 
both flucloxacillin groups. The study found the ‘peak incidence of Acute Kidney Injury 
(AKI) clearly coincides with the use of high dose flucloxacillin with single dose gentamicin’. 
Six of seven cases of renal failure (RIFLE Class F) (78) occurred in the high dose 
flucloxacillin group compared with one in the low dose flucloxacillin group. 
 
Eighteen (41, 49, 54, 58, 61-72, 74, 75) studies reported nephrotoxicity or ototoxicity 
following gentamicin. The majority of reports relate to nephrotoxicity, with only one 
reporting ototoxicity. A definition of nephrotoxicity or AKI was often absent or varied 
between studies (Figure 2). Where available the definition used by a particular study has been 
provided.
 *Measurements from original article in brackets. We have corrected a suspected error in the units of measurements. 
Attempts to contact the study author to clarify were unsuccessful. 17 
Bailey et al (49) compared a single dose of gentamicin with multiple dosing, as treatment for 
acute pyelonephritis, with 26 patients receiving a single dose and 27 multiple doses. Two 
episodes of nephrotoxicity defined as a rise in creatinine concentration >45µmol/l) were 
reported in the single dose group, compared to none in the multiple dose group. The first case 
was a 20 year old female with a rise in creatinine from 60 µmol/l to 170 µmol/l (0.06mmol/l 
to 0.17 mmol/l*) which was attributed to a short course of naproxen, taken 48 hours prior to 
gentamicin. The creatinine returned to normal within five days. The second case was a 19 
year old woman who had a transient rise in plasma creatinine from 60 µmol/l to 120 µmol/l 
(0.06 mmol/l to 0.12 mmol/l*), with a return to baseline the following day, which was 
attributed to salt and water depletion. Ototoxicity was defined as a 10dB or more loss in at 
least two frequencies in both ears and was reported in 3 of 18 patients in the single dose 
group and 7 of 23 in the multiple dose group, but no further information about these patients 
or their subsequent progress was given. 
 
Rakovec et al (54) included 1004 participants given either a single dose of gentamicin plus 
metronidazole or no antibiotics, prior to colorectal surgery. A large number of participants, 
749, had a diagnosis of carcinoma and 255 had ‘other diseases’ which were not specified. 
Blood tests were used to monitor adverse events and a total of 38 events were reported. 
Nineteen patients had a transient rise in creatinine level, 13 patients had a short-lived increase 
in Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvic 
Transaminase (SGPT), two patients had eosinophilia and four exhibited an exanthema. We 
have assumed that these adverse effects were seen in the antibiotic prophylaxis group, 
although this was not made explicit in the published article. 
 
Solgaard et al (41), a cohort study, compared dicloxacillin plus gentamicin to placebo as pre-
operative prophylaxis in patients with intertrochanteric hip fractures. This study recruited 163 
patients, up to 101 years old and excluded those with a pre-operative creatinine >121µmol/L. 
The study focused on nephrotoxicity, providing a clear definition of reversible and 
irreversible nephrotoxicity and description of how renal function was monitored. The group 
that received gentamicin had a median rise in creatinine, 17.2 µmol/L. This was significantly 
greater than the placebo group, which saw no rise in creatinine. However, at day seven post-
op no significant difference was seen in creatinine levels compared to baseline in either the 
antibiotic or placebo group. One case of irreversible nephrotoxicity, defined as increasing 
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 uraemia which led to death, occurred in the gentamicin group. No further details about this 
individual were given. 
 
Giri et al (58) was one of only two randomised studies published in the last 16 years. AKI, 
defined as a sudden (within 48 hours) decrease in renal function using Acute Kidney Injury 
Network Staging (79), was reported in both groups. All patients with AKI had a normal 
serum creatinine at one month follow up, without any further intervention. In non-randomised 
studies by Craig et al (74), Bailey et al (65), Craxford et al (66), Cobussen et al (71), Ahmed 
et al (70) and Dubrovskaya et al (69) no significant difference in rates of AKI were reported 
between gentamicin and comparator arms. In the majority of cases reported by Bailey et al 
(65), Cobussen et al (71), Ahmed et al (70) and Dubrovskaya et al (69) renal function 
returned to normal by the end of the follow up period. Bailey et al (65) reported 24 (9.4%) 
episodes of AKI (80), of which 21 had resolved at seven days post-op. Two of the three 
patients whose AKI persisted had a normal creatinine at 28 days and 32 days. The third 
patient was lost to follow up, but had a normal creatinine at 23 months. Cobussen et al (71) 
compared creatinine on and after admission, as well as between the gentamicin and control 
groups. After admission there was no difference in the incidence and severity of AKI 
between the gentamicin and control groups. At 8-14 days after admission most patients 
returned to their baseline creatinine. Ahmed et al (70) reported that of those who developed 
AKI (81) post-operatively, 80% of those in the gentamicin group and 79% in the cefuroxime 
group had resolution prior to discharge. Dubrovskaya et al (69) reported that 76.9% of 
patients with nephrotoxicity (80) in the gentamicin group and 82.6% in the control group had 
a creatinine within normal limits at the time of discharge, p = 0.703. Sprowson et al (63) 
found that many of their participants had a transient rise in creatinine but in their analysis the 
authors only included participants with acute renal failure requiring High Dependency Unit 
(HDU) admission. Although the numbers were small in both groups, there was a significant 
difference in the frequency of HDU admission between patients who received gentamicin 
(0.33%) and those who received cefuroxime (0.07%) - p = <0.01. The authors speculated that 
the threshold for admission to HDU may have been lower in the more recent years when 
gentamicin was used, (October 2007 – February 2009), compared to the comparator group 
who received cefuroxime from May 2002 – September 2007. 
 
Studies including Nielson et al (61), Mukherjee et al (62), Ross et al (75), Sprowson et al 
(63), Bell et al (64), Craxford et al (67), Nielson et al (68) and Walker et al (72) found 
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significant differences between groups receiving single dose gentamicin and those who did 
not. Nielson et al (61), Mukherjee et al (62) and Nielson et al (68) analysed creatinine 
between 24-72 hours post-operatively and Ross et al (75) performed their evaluation 
immediately post-operatively. None of these studies provided data beyond four days after 
treatment. Both studies by Nielson et al (61, 68) reported no statistically significant 
difference in the frequency of post-operative dialysis and in one (68) there was no difference 
in the median maximum serum creatinine after 72 hours. 
 
Bell et al (64) was the largest cohort study identified and assessed the risk of AKI in patients 
receiving antibiotic prophylaxis before surgery, across five different surgical specialities. 
Unfortunately data and publication errors in the descriptive data tables, make it difficult to 
interpret the original data. The study reports an increase in rates of AKI in patients receiving 
gentamicin who underwent orthopaedic surgery, with the majority of AKI being transient 
Stage 1 (82). There was no association between AKI and gentamicin in urology, vascular, 
gastrointestinal or gynaecology surgical patients. The same NHS Trust also published Walker 
et al (72), the second largest cohort study. This assessed post-operative AKI in patients who 
had neck of femur (NOF) repair operations or other orthopaedic surgery. For this review we 
included only data provided for patients undergoing orthopaedic surgery other than NOF 
repair, as only this group received a single dose of gentamicin. The majority (83%) of AKI 
seen in both treatment groups was Stage 1 (82), with 9.86% reported in the gentamicin group 
and 8.03% in the co-amoxiclav comparison group. Similar small differences were also seen 
in rates of Stage 2 and 3 AKI. There is no comment on whether these differences were 
statistically significant but the authors suggest that changes in practice, such as anaesthetic 
technique and post-operative care may have contributed to the differences seen. 
 
Craxford et al (67) found a statistically significant increase in AKI (80) between elective 
lower limb arthroplasty patients who received gentamicin plus flucloxacillin, compared to 
those who received cefuroxime (p = <0.01) but there was no significant difference in the 
frequency of haemofiltration between the groups. The difference in rates of AKI appeared to 
be independent of potential confounders and was not seen in a subgroup analysis of patients 
undergoing different surgical procedures. AKI was commoner in the Total Knee Replacement 
(TKR) group, but not in the Total Hip Replacement (THR) group which might be related to 
the use of a pneumatic tourniquet in the TKR group.  
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No meta-analysis was undertaken due to heterogeneity of the studies in relation to wide 
variations in patient demographics, co-morbidities, doses of gentamicin, study design and 
reporting of adverse events. 
 
 N/A – Not Applicable. * Denominator varies or is unclear. † RIFLE criteria (Risk Injury Failure Loss End-stage kidney disease).         21 
Table 2: Table of Adverse Events Data 
 
Study 
(Year of publication) 
Number of 
adverse 
events in all 
study arms 
Comparator Arm Frequency of 
adverse events 
in comparator 
group 
Type of adverse event reported in 
comparator group 
Adjunctive 
antibiotics in 
Gentamicin 
group 
Frequency of 
adverse events 
in gentamicin 
group 
Type of adverse event reported in 
gentamicin group 
Adelman et al          (1982) 0 Tobramycin 0/10 N/A Nil 0/10 N/A 
Ahmed et al 
 
(2016) 
303 
Some patients 
had >1 event 
Cefuroxime 117/744 Post-op Acute kidney injury (63) 
Thirty day mortality (54) 
Flucloxacillin 186/756 Post-op Acute kidney injury (125) 
Thirty day mortality (61) 
Bailey et al 
(1996) 
19 Multiple dose gentamicin 
+ ciprofloxacin 
13/25 Ototoxicity (7) Disturbed LFT's (5) 
Other (1) 
Ciprofloxacin 6* Nephrotoxicity (2), ototoxicity (3), 
disturbed LFTs (1) 
Bailey et al 
(2014) 
28 Cefuroxime 4/238 Acute kidney injury by RIFLE† 
R = (4) 
Flucloxacillin 24/254 Acute kidney injury by RIFLE† 
R = (12)  I = (7)  F = (5) 
Bell et al 
 
(2014) 
1370 Cefuroxime or 
Coamoxiclav 
548* Acute kidney injury (548) Flucloxacillin 
and/or 
Metronidazole 
822* Acute kidney injury (822) 
Challagundla et al 
 
(2013) 
48 Cefuroxime 11/100 Acute kidney injury by RIFLE 
R = (10)  I = (1) 
Flucloxacillin 
(High or Low 
dose) 
37/98 Acute kidney injury by RIFLE 
R = (22)  I = (8)  F = (7) 
Cobussen et al 
 
(2016) 
41 Broad spectrum ß-lactam 
antibiotic or 
fluoroquinolones 
21/123 Acute kidney injury by RIFLE 
R = (3)  I = (1)  F = (0) 
28-day mortality (17) 
Broad spectrum 
ß-lactam 
antibiotic 
36/179 Acute kidney injury by RIFLE 
R = (4)  I = (5)  F = (3) 
28-day mortality (24) 
Contrepois et al 
(1985) 
0 Dibekacin or tobramycin 
or netilmicin or amikacin 
0/24 N/A Nil 0/6 N/A 
Craig et al 
 
(2012) 
13 Cefuroxime 5/100 Reversible acute kidney injury (1) 
Not reversible acute kidney injury 
(4) 
Co-Amoxiclav 8/100 Reversible acute kidney injury (5) 
Not reversible acute kidney injury 
(3) 
Craxford et al 
(2014) 
18 Cefuroxime 2/200 Acute kidney injury by RIFLE 
R = (2) 
Flucloxacillin 16/200 Acute kidney injury by RIFLE 
R = (9)  I + F = (7) 
Craxford et al 
(2014) 
Not available Cefuroxime Not available No significant difference in acute 
kidney injury rates (p = 0.053) 
Flucloxacillin Not available No significant difference in acute 
kidney injury rates (p = 0.053) 
Creasey et al 
 
 
(1984) 
9 Aztreonam + cephradine 
or clindamycin or 
metronidazole or 
naficillin 
8/36 Transient taste disturbance, 
transient rise in serum glutamic 
pyruvic transaminase, transient rise 
in serum creatine phosphokinase 
Aztreonam 1/12 Transient rise in glutamic pyruvic 
transaminase 
Dobbs et al               (1976) 0 Tobramycin 0/6 N/A Nil 0/6 N/A 
Dubrovskaya et al 
 
(2015) 
85 Cefazolin 46/2587 Acute kidney injury by RIFLE 
R = (33)  I = (10)  F = (3) 
Cefazolin or 
clindamycin or 
vancomycin 
39/1590 Acute kidney injury by RIFLE 
R = (26)  I = (12)  F = (1) 
Fried et al 
(1996) 
17 Oral antibiotic based on 
urine culture sensitivity. 
10/70 Fever, haematuria, dysuria Nil 7/72 Fever, haematuria, dysuria 
Giri et al 
(2016) 
20 Amikacin + 
Metronidazole 
8/50 Acute kidney injury Stage 1 (8) Metronidazole 12/50 Acute kidney injury Stage 1 (10) 
Acute kidney injury Stage 2 (2) 
Hira et al                 (1985) 0 Kanamycin 0* N/A Nil 0* N/A 
Jahre et al                (1978) 0 Netilmicin 0/6 N/A Nil 0/6 N/A 
 N/A – Not Applicable. * Denominator varies or is unclear. † RIFLE criteria (Risk Injury Failure Loss End-stage kidney disease).         22 
 
Jettoo et al               (2013) 49 Cefuroxime 33/113 180 day mortality (33) Amoxicillin 16/107 180 day mortality (16) 
Kircaldy et al 
 
 
(2014) 
306 
Some patients 
had >1 event 
Gemifloxacin + 
azithromycin 
167/199 
Some patients 
had >1 event 
 
Nausea (74), Vomiting (10), Abdo 
pain (21), Diarrhoea (46), Fatigue 
(6), Dizziness (7), Tendon disorder 
(3) 
Azithromycin 139/202 
Some patients 
had >1 event 
 
Nausea (56), Vomiting (15), Abdo 
pain (15), Diarrhoea (39), Fatigue 
(4), Dizziness (7), Injection site pain 
(2), tendon disorder (1) 
Kleinschmidt et al     
(1983) 
4 Amoxicillin 4/31 Nausea (mild to significant) Nil 0/34 N/A 
Lorber et al 
(2013) 
0 Ofloxacin or 
Ciprofloxacin 
0/581 N/A Ofloxacin or 
Ciprofloxacin 
0/1085 N/A 
McEntee et al          (1987) 0 No treatment 0/44 N/A Nil 0/17 N/A 
Meyers et al             (1972) 0 Tobramycin 0/20 N/A Nil 0/16 N/A 
Mukherjee et al       (2013) 24 Not available Not available Not available Not available 24/40 Nephrotoxicity (24) 
Ndele 7 
Some patients 
had >1 event 
Netilmicin 3/6 
Some patients 
had >1 event 
Transient earthy taste (2)  
Transient smell of alcohol (2) 
Light headedness 5-10mins (3) 
Nil 0/6 N/A 
Nielson et al             (2013) 
Frequencies extrapolated 
from available published data 
865 
 
Teicoplanin and 
Dicloxacillin 
340/1307 Acute kidney injury (297) 
Postoperative dialysis (43) 
Teicoplanin and 
Dicloxacillin 
525/1716 Acute kidney injury (465) 
Postoperative dialysis (60) 
Nielson et al 
 
(2014) 
288 
Some patients 
had >1 event 
Teicoplanin and 
Dicloxacillin 
126/668 Acute kidney injury (110) 
1 year mortality (16) 
Teicoplanin and 
Dicloxacillin 
162/668 Acute kidney injury (145) 
1 year mortality (17) 
Pareek et al                
(1981) 
0 Spectinomycin 0/20 N/A Nil 0/20 N/A 
Pons et al 
(1993) 
6 Ceftizoxime 0/422 N/A Vancomycin 6/404 Clinically significant hypotension 
and/or flushing ('red man syndrome') 
Rakovec et al 
 
 
(1985) 
38 No treatment Not available Not available Metronidazole 38/572 Transient elevation of creatinine 
(19), short-lived increase 
SGOT+SGPT (13), eosinophilia (2), 
exanthema (4) 
Ross et al 
(2013) 
11 Cefuroxime 2/124 Acute kidney injury by RIFLE 
R = (2) 
Flucloxacillin 9/149 Acute kidney injury by RIFLE 
R = (4)  I = (3)  F = (2) 
Rowlands et al         (1982) 0 Placebo 0/62 N/A Clindamycin 0/67 N/A 
Solgaard et al 
(2000) 
21 No treatment 4/76 Reversible nephrotoxicity (4) Dicloxacillin 17/87 Irreversible nephrotoxicity (1) 
Reversible nephrotoxicity (16)  
Sprowson et al 
(2013) 
11 Cefuroxime + gentamicin 
loaded cement 
4/6094 Acute renal failure requiring High 
Dependency Unit (4) 
Gentamicin 
loaded cement 
7/2101 Acute renal failure requiring High 
Dependency Unit (7) 
Sundman et al 
(1997) 
4-5 Cefotaxime + norfloxacin 4 or 5/47 (inc 2 
or 3 deaths) 
Not available Norfloxacin 0/54 N/A 
Walker et al 
 
(2016) 
1031 Co-amoxiclav 273/2975 Acute kidney injury Stage 1 (239) 
Acute kidney injury Stage 2 (22) 
Acute kidney injury Stage 3 (12) 
Flucloxacillin 758/6267 Acute kidney injury Stage 1 (618) 
Acute kidney injury Stage 2 (95) 
Acute kidney injury Stage 3 (45) 
Wenzel et al 
(1985) 
1 Multiple dose gentamicin 
+ ornidazole 
1/30 Death Ornidazole 0/30 N/A 
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Discussion 
Our systematic review suggests that single dose gentamicin can have an effect on renal 
function, but this is usually mild and/or transient. Of the 38 studies identified, there were 
2601 episodes of creatinine rise or nephrotoxicity in the gentamicin group. This compares 
to 1424 episodes in the comparator arms. However many cases resolved within a few 
days or weeks or occurred in populations with renal risk factors. Three cases of 
ototoxicity were reported, all from a single study in which the comparator arm had a 
similar proportion of cases identified.  
 
In patients receiving multiple interventions it can be difficult to identify the relative 
contribution of a single agent to reported adverse effects. In particular other factors such 
as concomitant medication, pre-existing co-morbidities and surgical procedures can affect 
the risk of kidney injury. The studies (63-65, 67, 70, 72) that reported a statistically 
significant increase in AKI were all carried out in patients undergoing orthopaedic 
surgery. It is likely that patients are more vulnerable to the renal effects of gentamicin if 
they are older or are taking NSAIDs for joint pain.  
 
Cohort studies contributed the largest proportion of data to the review with an associated 
risk of unidentified confounding factors leading to bias. The majority of studies used 
antibiotic combination regimens, again making it difficult to identify the specific role of 
gentamicin. Flucloxacillin alone is not a common cause of nephrotoxicity, but 
Challagundlla et al (60) reported a difference in AKI between high and low dose 
flucloxacillin groups when all other confounders were accounted for. Whether 
flucloxacillin has a synergistic effect to cause gentamicin toxicity is unclear, but studies 
with adjunctive antibiotics need to be interpreted with caution. Only one study (63) 
published after 1996 did not use an adjunctive antibiotic in combination with gentamicin. 
 
The quality of studies was generally poor, specifically in defining and reporting adverse 
events, and especially for studies reporting prior to 2012. The risk of bias was therefore 
high or uncertain for many studies. Reporting of adverse events was often limited to one 
or two sentences commenting on a lack of side effects. This limited data on adverse 
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events also makes it difficult to identify specific subgroups that might be at higher risk of 
toxicity. Poor reporting of adverse events is a common problem even in otherwise high 
quality trials (41, 42). We were also unable to obtain 47 (5%) of the 933 potentially 
relevant reports. The majority (n=38) of these were conference abstracts, proceedings, 
dissertations or theses. Thirty of these 47 records also lacked a published abstract. 
 
Potential exclusion of relevant studies was minimised by the use of a robust search 
strategy and adherence to established protocols published by the Cochrane group (36) and 
Centre for Reviews and Dissemination at University of York.(83) Our 
inclusion/exclusion criteria were pre-defined and the only change from the published 
protocol was to expand the inclusion criteria to include foreign language papers. Limiting 
the analysis to studies which had a comparator group provided a more robust evaluation 
of which adverse effects were associated with gentamicin use. 
 
A relatively new indication for gentamicin is for the treatment of gonorrhoea. 
Gonorrhoea has been increasing in men and women in England since 2010, with a 21% 
increase between 2014-15(84). Multi drug resistance is common and an outbreak of 
highly level resistance to azithromycin was recently reported in England (85). The World 
Health Organisation has listed Neisseria gonorrhoeae as a high priority pathogen for 
research and development of new antibiotics(86). Two systematic reviews have showed 
that single dose gentamicin is an effective treatment (29, 31) and this has been supported 
by a large clinical trial(30). This systematic review supports the use of single dose 
gentamicin as a safe alternative treatment for gonorrhoea. 
 
Previous reports have found that repeated single daily dosing of aminoglycosides has an 
equivalent or lower level of toxicity compared to multiple daily doses (23). Other anti-
microbials have also shown an improved side effect profile when used as single dose 
daily therapy(87) but our review is the first to assess the toxicity of a single, one-off, dose 
of gentamicin. 
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